Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. CL
3. SNDK
4. TAP
5. DELL
6. ROIV
7. ANET
8. NKE
9. PANW
10. SPG

Go back to Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet
(NASDAQ: RCKT) Delayed: 3.86 +0.07 (1.85%)
Previous Close $3.79    52 Week High $ 
Open $3.75    52 Week Low $ 
Day High $3.88    P/E N/A 
Day Low $3.73    EPS $ 
Volume 888,541